Clinical stage pharmaceutical development Company
Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: BTHCF, Forum) stated on Monday that its lead compound to treat a type of chronic lung disease, NP-120, contains a key ingredient for its research program - a drug called
Ifenprodil. In two studies conducted by the Company, NP-120 outperformed the world’s leading two treatments for idiopathic pulmonary fibrosis (IPF).
For more on this news,
click here.
Earlier this month,
the Company filed a preliminary short form prospectus in connection with a fully marketed public offering of units for minimum gross proceeds of $2.5 million and maximum gross proceeds of $5 million.
FULL DISCLOSURE: Algernon Pharmaceuticals Inc. is a client of Stockhouse Publishing.